BASF to Establish World-Scale Specialty Amines Plant in Nanjing, China
BASF will build a new world scale production plant to manufacture specialty amines at its existing wholly-owned site in the Nanjing Chemical Industry Park in China. The plant, which is scheduled to come on stream in late 2015, will have dimethylaminopropylamine (DMAPA) and polyetheramines (PEA) as the main products. With this new facility BASF will further strengthen its global production network. The new plant complements existing facilities in Germany and the US for DMAPA and PEA.
“BASF is a leading supplier of DMAPA and PEA globally, and this investment reflects our continued commitment to meeting the growing market demand in Asia Pacific,” said Sanjeev Gandhi, President of BASF’s Intermediates division. “Our ability to produce these products within the region will strengthen our supply reliability and better serve our customers with shorter lead times.”
“The investment is driven by the increasing consumption of personal care products by the growing middle class in China and in Asia,” said Dr Guido Voit, Senior Vice President, BASF Intermediates, Asia Pacific. “Additionally, the development in the construction, wind energy and coatings industries in China and other emerging countries in Asia will continue to drive demand for PEA.”
DMAPA is mainly consumed in the production of betaines, which are used as co-surfactants in personal care products like shampoo and body wash. DMAPA is also used in various other applications including dye-stuff intermediates, lubricant additives, electroplating, coupling agents for rubber and others.
PEA is an intermediate chemical for epoxy curing agents used in the production of plastics, polyurea coatings, adhesives, reaction injection moulding and wind blade composites. BASF offers polyetheramines under its Baxxodur brand.
BASF has manufacturing capacities for both products at its sites in Ludwigshafen, Germany, and in Geismar, Louisiana.
For further information, click here.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance